20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evommune, Inc. (EVMN) operates in the NYSE industry and is headquartered in Palo Alto, United States with about 48 employees. Its market capitalization is roughly $244 million. In the fiscal year ended 2025-12-31, EVMN reported $13M in revenue and ($69M) in net income.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Interactive charts & full statements → Open the EVMN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | $10M | $13M | $7M | $5M |
| Gross Profit | — | $13M | $6M | $4M |
| Gross Margin % | — | 100.0% | 81.6% | 80.0% |
| Operating Income (EBIT) | ($102M) | ($81M) | ($70M) | ($38M) |
| Operating Margin % | -1018.9% | -623.6% | -1000.2% | -757.0% |
| Net Income | ($95M) | ($69M) | ($67M) | ($34M) |
| Net Margin % | -946.7% | -529.8% | -954.4% | -681.1% |
| EBITDA | ($96M) | ($67M) | ($65M) | ($33M) |
| Earnings Per Share (EPS) | $-2.83 | $-2.18 | $-2.22 | $-1.13 |
| Shares Outstanding (M) | 36M | 32M | 30M | 30M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $10M | — | $3M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $10M | $0M | $3M | — | — |
| Gross Margin % | — | — | — | 100.0% | — | 87.4% | — | — |
| Operating Income (EBIT) | ($35M) | ($24M) | ($30M) | ($13M) | ($23M) | ($15M) | ($19M) | ($17M) |
| Operating Margin % | — | — | — | -133.3% | — | -501.1% | — | — |
| Net Income | ($32M) | ($22M) | ($28M) | ($12M) | ($14M) | ($15M) | ($18M) | ($16M) |
| Net Margin % | — | — | — | -124.8% | — | -485.2% | — | — |
| EBITDA | ($34M) | ($21M) | ($28M) | ($12M) | ($13M) | ($14M) | ($18M) | — |
| Earnings Per Share (EPS) | $-0.89 | $-0.64 | $-0.90 | $-0.40 | $-0.45 | $-0.48 | $-0.61 | — |
| Shares Outstanding (M) | 36M | 34M | 32M | 32M | 30M | 30M | 30M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($74M) | ($76M) | ($58M) | ($30M) |
| Capital Expenditures (CapEx) | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($75M) | ($77M) | ($58M) | ($30M) |
| FCF Margin % | -746.5% | -589.8% | -832.6% | -601.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($20M) | ($28M) | ($17M) | ($10M) | ($26M) | ($24M) | ($19M) | ($26M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($20M) | ($28M) | ($17M) | ($10M) | ($26M) | ($24M) | ($19M) | ($26M) |
| FCF Margin % | — | — | — | -97.7% | — | -796.6% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets | $302M | $225M | $76M | $82M |
| Cash & Cash Equivalents | $60M | $44M | $16M | $29M |
| Total Liabilities | $24M | $19M | $220M | $160M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $1M |
| Total Shareholders' Equity | $278M | $206M | ($144M) | ($78M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EVMN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms